Literature DB >> 18688785

Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome.

Susan K Peterson1, Rebecca D Pentz, Salma K Marani, Patricia A Ward, Amie M Blanco, Denise LaRue, Kristen Vogel, Tamara Solomon, Louise C Strong.   

Abstract

OBJECTIVE: Li-Fraumeni syndrome (LFS) confers an increased risk of multiple types of cancer in both children and adults. Clinical genetic testing for deleterious germline p53 gene mutations can identify most LFS-affected families. We evaluated factors associated with cancer-specific distress and perceived self-efficacy in coping with a positive genetic test result among persons at risk of having deleterious p53 mutations.
METHODS: One hundred thirty-five persons from 15 LFS-affected families were invited to take part in a study that offered p53 genetic counseling and testing and to complete psychosocial measures.
RESULTS: Participants (n=92) were more likely to be younger and female than nonparticipants (n=43). In multivariate analyses, greater cancer-specific distress was associated with having a lower quality of life, a higher perceived risk of having a p53 mutation, no personal history of cancer and a greater number of first degree relatives (FDRs) affected with cancer. Lower perceived self-efficacy in coping with a positive test result was associated with greater cancer worry, higher decisional conflict about p53 testing and having no personal history of cancer.
CONCLUSIONS: Individual perceptions about cancer risk and p53 genetic testing, as well as personal experience with FDRs' cancer diagnoses and deaths, should be addressed during the counseling and testing process for LFS-affected families.

Entities:  

Mesh:

Year:  2008        PMID: 18688785      PMCID: PMC9535398          DOI: 10.1002/pon.1352

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.955


  32 in total

1.  Looking forward and back: distress among women at familial risk for breast cancer.

Authors:  J Erblich; D H Bovbjerg; H B Valdimarsdottir
Journal:  Ann Behav Med       Date:  2000

2.  Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome.

Authors:  G Bougeard; J M Limacher; C Martin; F Charbonnier; A Killian; O Delattre; M Longy; P Jonveaux; J P Fricker; D Stoppa-Lyonnet; J M Flaman; T Frébourg
Journal:  J Med Genet       Date:  2001-04       Impact factor: 6.318

3.  American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.

Authors:  Debbie Saslow; Carla Boetes; Wylie Burke; Steven Harms; Martin O Leach; Constance D Lehman; Elizabeth Morris; Etta Pisano; Mitchell Schnall; Stephen Sener; Robert A Smith; Ellen Warner; Martin Yaffe; Kimberly S Andrews; Christy A Russell
Journal:  CA Cancer J Clin       Date:  2007 Mar-Apr       Impact factor: 508.702

4.  Attitudes toward colon cancer gene testing: factors predicting test uptake.

Authors:  A M Codori; G M Petersen; D L Miglioretti; E K Larkin; M T Bushey; C Young; J D Brensinger; K Johnson; J A Bacon; S V Booker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-04       Impact factor: 4.254

5.  Psychological functioning of daughters of breast cancer patients. Part II: Characterizing the distressed daughter of the breast cancer patient.

Authors:  D K Wellisch; E R Gritz; W Schain; H J Wang; J Siau
Journal:  Psychosomatics       Date:  1992       Impact factor: 2.386

Review 6.  Psychological impact of genetic testing for cancer susceptibility: an update of the literature.

Authors:  Bettina Meiser
Journal:  Psychooncology       Date:  2005-12       Impact factor: 3.894

7.  Psychological functioning of daughters of breast cancer patients. Part I: Daughters and comparison subjects.

Authors:  D K Wellisch; E R Gritz; W Schain; H J Wang; J Siau
Journal:  Psychosomatics       Date:  1991       Impact factor: 2.386

8.  Cancer in survivors of childhood soft tissue sarcoma and their relatives.

Authors:  L C Strong; M Stine; T L Norsted
Journal:  J Natl Cancer Inst       Date:  1987-12       Impact factor: 13.506

9.  Factors associated with breast cancer-specific distress in younger women participating in a family history mammography screening programme.

Authors:  B J Henderson; S Tyndel; K Brain; A Clements; C Bankhead; J Austoker; E Watson; Stephen Duffy; Gareth Evans; Hilary Fielder; Jonathon Gray; James Mackay; Douglas Macmillan
Journal:  Psychooncology       Date:  2008-01       Impact factor: 3.894

10.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals.

Authors:  A Chompret; L Brugières; M Ronsin; M Gardes; F Dessarps-Freichey; A Abel; D Hua; L Ligot; M G Dondon; B Bressac-de Paillerets; T Frébourg; J Lemerle; C Bonaïti-Pellié; J Feunteun
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

View more
  15 in total

1.  Next generation sequencing is informing phenotype: a TP53 example.

Authors:  R O'Shea; R Clarke; E Berkley; C Giffney; M Farrell; E O'Donovan; D J Gallagher
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

2.  Should pretest genetic counselling be required for patients pursuing genomic sequencing? Results from a survey of participants in a large genomic implementation study.

Authors:  Joel E Pacyna; Carmen Radecki Breitkopf; Sarah M Jenkins; Erica J Sutton; Caroline Horrow; Iftikhar J Kullo; Richard R Sharp
Journal:  J Med Genet       Date:  2018-12-22       Impact factor: 6.318

3.  Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome.

Authors:  June A Peters; Regina Kenen; Renee Bremer; Shannon Givens; Sharon A Savage; Phuong L Mai
Journal:  J Genet Couns       Date:  2015-11-30       Impact factor: 2.537

4.  Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

Authors:  Kate A McBride; Mandy L Ballinger; Timothy E Schlub; Mary-Anne Young; Martin H N Tattersall; Judy Kirk; Ros Eeles; Emma Killick; Leslie G Walker; Sue Shanley; David M Thomas; Gillian Mitchell
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

5.  Li-fraumeni syndrome.

Authors:  David Malkin
Journal:  Genes Cancer       Date:  2011-04

6.  TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.

Authors:  J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

Review 7.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

8.  On averages and peaks: how do people integrate attitudes about multiple diseases to reach a decision about multiplex genetic testing?

Authors:  Shoshana Shiloh; Christopher H Wade; J Scott Roberts; Sharon Hensley Alford; Barbara B Biesecker
Journal:  Med Decis Making       Date:  2012-11-05       Impact factor: 2.583

9.  Waiting and "weighted down": the challenge of anticipatory loss for individuals and families with Li-Fraumeni Syndrome.

Authors:  Allison Werner-Lin; Jennifer L Young; Catherine Wilsnack; Shana L Merrill; Victoria Groner; Mark H Greene; Payal P Khincha
Journal:  Fam Cancer       Date:  2020-07       Impact factor: 2.375

10.  The psychosocial effects of the Li-Fraumeni Education and Early Detection (LEAD) program on individuals with Li-Fraumeni syndrome.

Authors:  Jessica Ross; Jasmina Bojadzieva; Susan Peterson; Sarah Jane Noblin; Rebecca Yzquierdo; Martha Askins; Louise Strong
Journal:  Genet Med       Date:  2017-03-16       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.